The use of Alemtuzumab in multiple sclerosis patients in a clinical setting, Kuwait experience

被引：1
|
作者：
Alroughani, R. [1 ]
Ahmed, S. F. [2 ,3 ]
Behbehani, R. [4 ]
Al-Hashel, J. [2 ,5 ]
机构：
[1] Amiri Hosp Kuwait, Div Neurol, Dept Med, Kuwait, Kuwait
[2] Ibn Sina Hosp Kuwait, Neurol, Kuwait, Kuwait
[3] Alminia Univ Egypt, Fac Med, Neuropsychiat, Alminia, Egypt
[4] Albahr Ctr Kuwait, Neuroopthalmol, Kuwait, Kuwait
[5] Kuwait Univ, Med, Fac Med, Kuwait, Kuwait
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2017年 / 381卷
关键词：
D O I：
10.1016/j.jns.2017.08.672
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
644
引用
收藏
页码：235 / 235
页数：1
相关论文
共 50 条
  • [11] Preclinical and clinical evaluation of alemtuzumab in multiple sclerosis
    Siders, William
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [12] Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
    Havrdova, Eva
    Horakova, Dana
    Kovarova, Ivana
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 31 - 45
  • [13] Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
    Berger, Thomas
    Elovaara, Irina
    Fredrikson, Sten
    McGuigan, Chris
    Moiola, Lucia
    Myhr, Kjell-Morten
    Oreja-Guevara, Celia
    Stoliarov, Igor
    Zettl, Uwe K.
    CNS DRUGS, 2017, 31 (01) : 33 - 50
  • [14] Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
    Thomas Berger
    Irina Elovaara
    Sten Fredrikson
    Chris McGuigan
    Lucia Moiola
    Kjell-Morten Myhr
    Celia Oreja-Guevara
    Igor Stoliarov
    Uwe K. Zettl
    CNS Drugs, 2017, 31 : 33 - 50
  • [15] REAL WORLD EXPERIENCE OF TREATING MULTIPLE SCLEROSIS WITH ALEMTUZUMAB
    Khalili, Ellie
    Venning, Brent
    Boggild, Mike
    Broadley, Simon A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E33 - E33
  • [16] Demographics and Clinical Characteristics of Multiple Sclerosis in Kuwait
    Alroughani, Raed
    Ahmed, S. F.
    Al-Hashel, J.
    EUROPEAN NEUROLOGY, 2014, 72 (3-4) : 181 - 185
  • [17] Safety of alemtuzumab for multiple sclerosis after exposure to chemotherapeutic agents for patients with multiple sclerosis - experience of a single MS center
    Maldonado, D. A. Pimentel
    Yerokhin, O.
    Ararat, K.
    Umeton, R. Pizzolato
    Matzka, L.
    Ionete, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 381 - 381
  • [18] Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab
    Ines Gaitan, Maria
    Celica Ysrraelit, Maria
    Correale, Jorge
    JAMA NEUROLOGY, 2017, 74 (09) : 1143 - 1144
  • [19] The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
    Alroughani, Raed
    Van Wijmeersch, Bart
    Al Khaboori, Jabber
    Alsharoqi, Isa Ahmed
    Ahmed, Samar F.
    Hassan, Ali
    Inshasi, Jihad
    Krieger, Derk W.
    Shakra, Mustafa
    Shatila, Ahmed Osman
    Szolics, Miklos
    Khallaf, Mohamed
    Ezzat, Aly
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [20] Alemtuzumab for multiple sclerosis
    不详
    LANCET, 2012, 380 (9856): : 1792 - 1792
12345